Dermata Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Dermata Therapeutics Inc 's ROA in the second quarter of 2026?
Dermata Therapeutics Inc recorded a cumulative net loss of $-8 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -129.01%.

However, within the Healthcare sector 782 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4279, from total ROA ranking in the first quarter of 2026 at 4956.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-18.74 %	-25.38 %	2052.34 %	832.87 %	2194.17 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-8	-7	-8	-9	-10
Return On Assets (TTM)	-129.01 %	-104.49 %	-101.69 %	-160.22 %	-235.26 %
DRMA's Total Ranking	# 4279	# 4956	# 4496	# 4600	# 4721
Total Assets (TTM) in million	5	7	8	5	7
Seq. Total Assets Change	-27.72 %	-6.84 %	58.01 %	-23.63 %	-33.63 %
Seq. Net Income Change	-	-	-	-	-

DRMA's 5 Years Annual ROA >> Back to DRMA Management Effectiveness >> Compare DRMA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 366
Sector	# 783
Overall	# 4313

Return On Assets Statistics
High	Average	Low
-88.6 %	-126.17 %	-238.16 %
(Jun 30 2022)		(Dec 31 2024)

News about Dermata Therapeutics Inc Return on Assets ROA

Navigating Volatility Analyzing Dermata Therapeutics Stock Performance Amidst Market Turbulence and Clinical Ambiguities,

An In-Depth Analysis of Dermata Therapeutics Inc (DRMA): Stock Performance, Challenges, and Future Outlook Dermata Therapeutics Inc (NASDAQ: DRMA) is a late-stage biotechnology company focused on developing innovative treatments for medical and aesthetic skin conditions. The stock has been under the spotlight due to various news releases and market fluctuations recently, raising concerns and questions about its future potential. In this comprehensive article, we ll explore recent developments influencing Dermata s stock, its performance in comparison to the overall market, and an analysis of its financial health. Recent Stock Influences1. Price-to-Earnings Ratio Insights On August 1, 2024, an analysis of Dermata s price-to-earnings ratio highlighted a 36-month beta value of 0.61, indicating low volatility compared to the market. Surprisingly, the analysis also revealed no analysts rated DRMA as a buy, overweight, or hold. This lack of analyst confidence could deter potential investors, leading to a further decline in stock performance.2. Cognition Therapeutics Phase 2 Trial Fallout The stock took a hit on July 31, 2024, after Cognition Therapeutics reported disappointing Phase 2 trial results for Alzheimer’s disease. Although their product showed some cognitive benefits, the fading statistical significance over time led to a swift drop of over 40% in their shares. This market reaction influenced the overall sector, including Dermata s stock performance, which could indirectly face downward pressure due to investor sentiment.

Financial Statements
Dermata Therapeutics Inc 's Assets	$ 5 million	DRMA's Balance sheet
Dermata Therapeutics Inc 's Income	$ -3 million	Quarterly DRMA's Income Statement
DRMA's Income by Division		See DRMA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	2012.13 %	-31.12 %	-92.22 %	-40.26 %	-
Total Assets in million	8	0	1	7	12
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-8	-12	-8	-10	-8
Annual Return On Assets	-96.12 %	-3300.26 %	-1442.04 %	-138.4 %	-70.3 %

DRMA's 5 Years Annual ROA >> Back to DRMA Management Effectiveness >> Compare DRMA ROA to its Competitors

More Return On Assets Ratios
DRMA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
DRMA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for DRMA's Competitors
Subscribers only: Roa for Dermata Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for DRMA's Customers

You may also want to know
DRMA's Roi	DRMA's Inventory Turnover Ratio	DRMA's Growth Rates	DRMA's Dividend Comparisons
	DRMA's Profitability Ratios	DRMA's Asset Turnover Ratio	DRMA's Dividend Growth
DRMA's Roe	DRMA's Valuation Ratios	DRMA's Financial Strength Ratios	DRMA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-04T16:51:34+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.